In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Clinical Trials In 2019: Is Biopharma Ready To Tackle The Iron Triangle of Time, Cost and Quality?

The clinical trial embodies the hope and the hassle of biopharma’s mission to develop new drugs for patients. It is an endlessly imperfect process: C-suite calls for more efficiency and speed at lower cost has been the story for decades. But an In Vivo conversation with a leading expert on trial management pinpoints three key trends that suggest better days are ahead for this central pillar of the innovation imperative.

Clinical Trials Innovation BioPharmaceutical
Advertisement

Latest From Market Intelligence

2018 Completed Clinical Trials: Change Is The New Constant

Trialtrove’s annual review of clinical trials initiated by industry sponsors is a useful gauge of the diversity and innovative potential of biopharma’s investments in R&D. This year’s report reveals that, while there are patterns of consistency in many aspects of the trial landscape, changes are in the wind – particularly as companies outside the pharma top 20 now contribute more completed trials than any other type of sponsor.

Clinical Trials Market Intelligence

Deals Shaping The Medical Industry, August 2019

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2019.

Deals Financing

Deals In Depth: June 2019

Gilead signed two big oncology deals with Nurix and Carna. AbbVie bought Botox maker Allergan for $63 billion. FOPOs led biopharma financing, while debt represented the most dollars in device fundraising.

Deals Market Intelligence

A New Definition: The EU Answer To Medicines Shortages?

What is a medicines shortage? The answer may seem obvious, but the fact that European regulators have only now come up with a commonly agreed definition suggests otherwise.

Europe Life Cycle Management

Deals Shaping the Medical Industry, July 2019

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June 2019.

Deals Financing

Deals In Depth: May 2019

As it plans to focus on core therapy areas following the Shire acquisition, Takeda divested dry eye drug Xiidra to Novartis for up to $5.3bn. 3M bought wound care firm Acelity  from an investor consortium led by Apax partners for $6.7bn. Both pharma and device financing was up over the previous month, with strong showings from debt offerings.

Deals Market Intelligence
See All
UsernamePublicRestriction

Register